Is high-dose stereotactic body radiotherapy (SBRT) for stage i non-small cell lung cancer (NSCLC) overkill? A systematic review

Angela Van Baardwijk, Wolfgang A. Tome, Wouter Van Elmpt, Soren M. Bentzen, Bart Reymen, Rinus Wanders, Ruud Houben, Michel Öllers, Philippe Lambin, Dirk De Ruysscher

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background and purpose: For stereotactic body radiotherapy (SBRT), typically a scheme of 60 Gy in 3-8 fractions is applied, producing local tumour control rates around 90%. The dose specification is in one point only and ignores possible underdosages at the edge of the planning target volume (PTV). We investigated the doses at the edge of the PTV and correlated this with local tumour control with the aim to shed light on the radiation dose needed to eradicate stage I NSCLC. Materials and methods: Published data on the freedom from local progression (FFLP) data from SBRT and accelerated high-dose conventional radiotherapy series for stage I NSCLC with a follow up of at least 30 months were included. The EQD2,T was calculated from the dose at the periphery of the PTV. Results: Fifteen studies for SBRT (1076 patients) showed a median FFLP of 88.0 ± 10.4% with a median EQD2,T of 76.9 ± 17.4 Gy. The median FFLP was 87.6 ± 6.0% for the accelerated schedules with an EQD2,T of 86.9 ± 39.1 Gy, respectively. No significant relation was found between FFLP and the EQD 2,T (p = 0.23). Conclusions: Several fractionated and accelerated schedules with equal biological doses achieve the same tumour control rates as SBRT. Lower, but more uniform doses to the whole PTV may be sufficient to achieve similar control rates, with the possibility to deliver SBRT in adapted schedules, beneficial to centrally located tumours in the vicinity of critical structures like the oesophagus and great vessels.

Original languageEnglish (US)
Pages (from-to)145-149
Number of pages5
JournalRadiotherapy and Oncology
Volume105
Issue number2
DOIs
StatePublished - Nov 2012
Externally publishedYes

Fingerprint

Radiosurgery
Non-Small Cell Lung Carcinoma
Appointments and Schedules
Neoplasms
Esophagus
Radiotherapy
Radiation

Keywords

  • Lung cancer
  • Modelling
  • SABR
  • SBRT
  • Stage I
  • Stereotactic body radiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Cite this

Is high-dose stereotactic body radiotherapy (SBRT) for stage i non-small cell lung cancer (NSCLC) overkill? A systematic review. / Van Baardwijk, Angela; Tome, Wolfgang A.; Van Elmpt, Wouter; Bentzen, Soren M.; Reymen, Bart; Wanders, Rinus; Houben, Ruud; Öllers, Michel; Lambin, Philippe; De Ruysscher, Dirk.

In: Radiotherapy and Oncology, Vol. 105, No. 2, 11.2012, p. 145-149.

Research output: Contribution to journalArticle

Van Baardwijk, A, Tome, WA, Van Elmpt, W, Bentzen, SM, Reymen, B, Wanders, R, Houben, R, Öllers, M, Lambin, P & De Ruysscher, D 2012, 'Is high-dose stereotactic body radiotherapy (SBRT) for stage i non-small cell lung cancer (NSCLC) overkill? A systematic review', Radiotherapy and Oncology, vol. 105, no. 2, pp. 145-149. https://doi.org/10.1016/j.radonc.2012.09.008
Van Baardwijk, Angela ; Tome, Wolfgang A. ; Van Elmpt, Wouter ; Bentzen, Soren M. ; Reymen, Bart ; Wanders, Rinus ; Houben, Ruud ; Öllers, Michel ; Lambin, Philippe ; De Ruysscher, Dirk. / Is high-dose stereotactic body radiotherapy (SBRT) for stage i non-small cell lung cancer (NSCLC) overkill? A systematic review. In: Radiotherapy and Oncology. 2012 ; Vol. 105, No. 2. pp. 145-149.
@article{90583b808af74378a81dfdf70ab70c57,
title = "Is high-dose stereotactic body radiotherapy (SBRT) for stage i non-small cell lung cancer (NSCLC) overkill? A systematic review",
abstract = "Background and purpose: For stereotactic body radiotherapy (SBRT), typically a scheme of 60 Gy in 3-8 fractions is applied, producing local tumour control rates around 90{\%}. The dose specification is in one point only and ignores possible underdosages at the edge of the planning target volume (PTV). We investigated the doses at the edge of the PTV and correlated this with local tumour control with the aim to shed light on the radiation dose needed to eradicate stage I NSCLC. Materials and methods: Published data on the freedom from local progression (FFLP) data from SBRT and accelerated high-dose conventional radiotherapy series for stage I NSCLC with a follow up of at least 30 months were included. The EQD2,T was calculated from the dose at the periphery of the PTV. Results: Fifteen studies for SBRT (1076 patients) showed a median FFLP of 88.0 ± 10.4{\%} with a median EQD2,T of 76.9 ± 17.4 Gy. The median FFLP was 87.6 ± 6.0{\%} for the accelerated schedules with an EQD2,T of 86.9 ± 39.1 Gy, respectively. No significant relation was found between FFLP and the EQD 2,T (p = 0.23). Conclusions: Several fractionated and accelerated schedules with equal biological doses achieve the same tumour control rates as SBRT. Lower, but more uniform doses to the whole PTV may be sufficient to achieve similar control rates, with the possibility to deliver SBRT in adapted schedules, beneficial to centrally located tumours in the vicinity of critical structures like the oesophagus and great vessels.",
keywords = "Lung cancer, Modelling, SABR, SBRT, Stage I, Stereotactic body radiation",
author = "{Van Baardwijk}, Angela and Tome, {Wolfgang A.} and {Van Elmpt}, Wouter and Bentzen, {Soren M.} and Bart Reymen and Rinus Wanders and Ruud Houben and Michel {\"O}llers and Philippe Lambin and {De Ruysscher}, Dirk",
year = "2012",
month = "11",
doi = "10.1016/j.radonc.2012.09.008",
language = "English (US)",
volume = "105",
pages = "145--149",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Is high-dose stereotactic body radiotherapy (SBRT) for stage i non-small cell lung cancer (NSCLC) overkill? A systematic review

AU - Van Baardwijk, Angela

AU - Tome, Wolfgang A.

AU - Van Elmpt, Wouter

AU - Bentzen, Soren M.

AU - Reymen, Bart

AU - Wanders, Rinus

AU - Houben, Ruud

AU - Öllers, Michel

AU - Lambin, Philippe

AU - De Ruysscher, Dirk

PY - 2012/11

Y1 - 2012/11

N2 - Background and purpose: For stereotactic body radiotherapy (SBRT), typically a scheme of 60 Gy in 3-8 fractions is applied, producing local tumour control rates around 90%. The dose specification is in one point only and ignores possible underdosages at the edge of the planning target volume (PTV). We investigated the doses at the edge of the PTV and correlated this with local tumour control with the aim to shed light on the radiation dose needed to eradicate stage I NSCLC. Materials and methods: Published data on the freedom from local progression (FFLP) data from SBRT and accelerated high-dose conventional radiotherapy series for stage I NSCLC with a follow up of at least 30 months were included. The EQD2,T was calculated from the dose at the periphery of the PTV. Results: Fifteen studies for SBRT (1076 patients) showed a median FFLP of 88.0 ± 10.4% with a median EQD2,T of 76.9 ± 17.4 Gy. The median FFLP was 87.6 ± 6.0% for the accelerated schedules with an EQD2,T of 86.9 ± 39.1 Gy, respectively. No significant relation was found between FFLP and the EQD 2,T (p = 0.23). Conclusions: Several fractionated and accelerated schedules with equal biological doses achieve the same tumour control rates as SBRT. Lower, but more uniform doses to the whole PTV may be sufficient to achieve similar control rates, with the possibility to deliver SBRT in adapted schedules, beneficial to centrally located tumours in the vicinity of critical structures like the oesophagus and great vessels.

AB - Background and purpose: For stereotactic body radiotherapy (SBRT), typically a scheme of 60 Gy in 3-8 fractions is applied, producing local tumour control rates around 90%. The dose specification is in one point only and ignores possible underdosages at the edge of the planning target volume (PTV). We investigated the doses at the edge of the PTV and correlated this with local tumour control with the aim to shed light on the radiation dose needed to eradicate stage I NSCLC. Materials and methods: Published data on the freedom from local progression (FFLP) data from SBRT and accelerated high-dose conventional radiotherapy series for stage I NSCLC with a follow up of at least 30 months were included. The EQD2,T was calculated from the dose at the periphery of the PTV. Results: Fifteen studies for SBRT (1076 patients) showed a median FFLP of 88.0 ± 10.4% with a median EQD2,T of 76.9 ± 17.4 Gy. The median FFLP was 87.6 ± 6.0% for the accelerated schedules with an EQD2,T of 86.9 ± 39.1 Gy, respectively. No significant relation was found between FFLP and the EQD 2,T (p = 0.23). Conclusions: Several fractionated and accelerated schedules with equal biological doses achieve the same tumour control rates as SBRT. Lower, but more uniform doses to the whole PTV may be sufficient to achieve similar control rates, with the possibility to deliver SBRT in adapted schedules, beneficial to centrally located tumours in the vicinity of critical structures like the oesophagus and great vessels.

KW - Lung cancer

KW - Modelling

KW - SABR

KW - SBRT

KW - Stage I

KW - Stereotactic body radiation

UR - http://www.scopus.com/inward/record.url?scp=84871336875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871336875&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2012.09.008

DO - 10.1016/j.radonc.2012.09.008

M3 - Article

C2 - 23068707

AN - SCOPUS:84871336875

VL - 105

SP - 145

EP - 149

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 2

ER -